<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01045395</url>
  </required_header>
  <id_info>
    <org_study_id>B2008:139</org_study_id>
    <nct_id>NCT01045395</nct_id>
  </id_info>
  <brief_title>Efficacy of Two Algae Formulations on Lipid Metabolism, Inflammation and Oxidative Stress Status in Individuals With Psoriasis</brief_title>
  <acronym>PCA</acronym>
  <official_title>Efficacy of Two Algae Formulations on Lipid Metabolism, Inflammation and Oxidative Stress Status in Individuals With Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our overall goal is to evaluate the safety and efficacy of consumption of two algae&#xD;
      formulations compared to a placebo on: degree of severity of skin lesions, plasma lipid&#xD;
      levels, as well as other health-related markers, in individuals with clinically diagnosed&#xD;
      psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A photographic documentation will be carried out quantifying lesion size over at least two body sites. A subjective questionnaire will also be provided to volunteers to enable self-reported evaluation of the extent and degree of discomfort of lesions.</measure>
    <time_frame>at the beginning and end of each of the three intervention periods</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total cholesterol, LDL- cholesterol, HDL-cholesterol and Triglycerides in plasma, will be determined.</measure>
    <time_frame>at the beginning and the end of each phase</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vascular cell adhesion molecule-1 (VCAM-1), E-selectin, interleukin-6 (IL-6), IL-10, soluble tumour necrosis factor receptor 2 (sTNFR-2) and soluble cell adhesion molecules (sICAM-1 and sVCAM-1) will be assessed. Lipid peroxidation will also be measured.</measure>
    <time_frame>at the beginning and the end of each phase</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Corn starch, 90mg/d</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Corn starch, 90mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unique Marine Algae Concentrate (UMAC). 90mg/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Golden brown algae, 90mg/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Corn starch</intervention_name>
    <description>90mg/d</description>
    <arm_group_label>Corn starch, 90mg/d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Unique Marine Algae Concentrate (UMAC)</intervention_name>
    <description>90mg/d</description>
    <arm_group_label>Unique Marine Algae Concentrate (UMAC). 90mg/d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Golden brown algae</intervention_name>
    <description>90mg/d</description>
    <arm_group_label>Golden brown algae, 90mg/d</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females with clinically diagnosed psoriasis&#xD;
&#xD;
          -  Plasma LDL-C 80-190 mg/dL, and TG levels below 400 mg/dL.&#xD;
&#xD;
          -  Body mass index (BMI) range will be 22 to 32 kg/m2.&#xD;
&#xD;
          -  Subjects must demonstrate an ability to understand dietary procedures and be judged as&#xD;
             compliant and motivated by the investigators.&#xD;
&#xD;
          -  Subjects will be permitted to take stable doses of medications (including drugs for&#xD;
             thyroid disease and hypertension)will be permitted if the dose level is maintained&#xD;
             stable throughout the study.&#xD;
&#xD;
          -  potential subjects must have stable psoriasis and their treatments must remain&#xD;
             constant throughout the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  recent (i.e. less than 3 mo) or chronic use of oral hypolipidemic therapy, including&#xD;
             fish oils, or probucol within the last 6 mo&#xD;
&#xD;
          -  history of chronic use of alcohol (&gt;2 drinks/d), systemic antibodies, corticosteroids,&#xD;
             androgens, or phenytoin&#xD;
&#xD;
          -  subjects on anticoagulant therapy (such as warfarin), taking medications and/or&#xD;
             natural health products known to affect lipid metabolism (cholestyramine, colestipol,&#xD;
             niacin, clofibrate, gemfibrozil, probucol, HMG CoA reductase inhibitors, high dose&#xD;
             dietary supplements or fish oil capsules (&gt;4g/day), guggul, lecithin, evening primrose&#xD;
             oil within the last six month period will be excluded. In addition, subjects will not&#xD;
             be allowed to consume any of these medications during the study&#xD;
&#xD;
          -  myocardial infarction, coronary artery bypass, or other major surgical procedures&#xD;
             within the last six months&#xD;
&#xD;
          -  recent onset and any history of angina, congestive heart failure, heart disease,&#xD;
             inflammatory bowel disease, pancreatitis, diabetes, lactose intolerance&#xD;
             gastrointestinal, renal, pulmonary, hepatic or biliary disease, or cancer&#xD;
&#xD;
          -  moderate or high risk for CAD&#xD;
&#xD;
          -  uncontrolled hypertension defined as untreated systolic blood pressure &gt; 160 mmHg&#xD;
             and/or diastolic blood pressure &gt; 100 mmHg&#xD;
&#xD;
          -  pregnant, breastfeeding, or planning to become pregnant during the course of the trial&#xD;
&#xD;
          -  bleeding disorder, anemia, or significant recent blood loss/donation&#xD;
&#xD;
          -  allergy/sensitivity to any of the ingredients in the study product or placebo&#xD;
&#xD;
          -  chronic user of algal products, fiber laxative (greater than 2 doses/wk), or stimulant&#xD;
             laxatives or has a history of eating disorders, exercise greater than 15 miles/wk or&#xD;
             4,000 kcal/wk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ricahrson Centre for Functionl Foods and Nutraceuticals, U of M</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <study_first_submitted>January 7, 2010</study_first_submitted>
  <study_first_submitted_qc>January 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2010</study_first_posted>
  <last_update_submitted>March 15, 2011</last_update_submitted>
  <last_update_submitted_qc>March 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Peter Jones Director Richardson Centre for Functional Foods and Nutraceuticals</name_title>
    <organization>Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba</organization>
  </responsible_party>
  <keyword>Algae</keyword>
  <keyword>Psoriasis</keyword>
  <keyword>Lipid metabolism</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Oxidative stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

